Seed Round · Q1 2027

$1.5M to take a fully modeled computational platform into the lab, clear the two gates that decide whether the valve works, and reach a functional prototype.

Round
Seed
Timing
Q1 2027
Amount
$1.5M
Pre-money
$6M
Post-money
$7.5M
Runway
18 months

The seed funds the move from model to measurement

Every computational phase is complete. The seed funds the transition to physical reality, and it starts with two biophysical measurements, each with a predefined success criterion, each run on standard instrumentation at an established core facility.

Both have clear failure paths with construct-level fixes already designed. When both clear, the same round carries the work through chassis construction and a prototype chip. We would rather tell you what we do not yet know than describe what we have modeled as though it were measured.

✓ Genome-scale metabolic model (iJDZ836)
✓ 10,440 KO pairs screened — 16 chip-eligible strains identified in silico
✓ LOV2-Jα-HEX1 + SPA1-ePDZ designed and modeled — per-domain pLDDT 91 & 88
✓ H-tree scaffold designed (10×10 mm, 16 ports)
✓ US provisional 64/087,071 filed — 5 claim families
→ Gate 1 (SEC-MALS) and Gate 2 (BLI) — the next work we do

Validation Sequence

Both gates clear before any chassis or chip work begins. Strain engineering is the expensive step, and there is no reason to spend it before the valve protein is known to behave.

G1

SEC-MALS on CompA_v3

Mw ≥ 1000 kDa, Mw/Mn < 1.5 (R_h ≥ 28 nm)

G2

BLI/SPR — Jα motif to ePDZ anchor

K_d ≤ 1 µM lit, ≥10× dark/lit contrast

M3

Six-gene chassis construction

PCR-verified knockouts

M4

Valve function in hypha (microscopy)

Reversible reduction in cross-septal transport at 450 nm

M5

Prototype chip colonization

Fluorescent flow through network

M6

First academic beta site

LOI from 3 labs

G1 and G2 are gates. Everything below them has a dashed border because it is contingent on both clearing. No month numbers are given: a gated plan should not promise dates it cannot control.

$1.5M seed — 18 months to a functional prototype

Sivoro runs no lab of its own, so the largest line is contracted work at core facilities. Spend is sequenced against the gates: protein validation first, chassis and chip work after both clear.

Allocation of the $1.5M seed round by category
Category Amount %
Contracted lab & core facilities

Core-facility access, SEC-MALS and BLI service contracts, consumables

$400k 27%
Strain construction

Contracted gene synthesis, cloning, and strain engineering · 18 months

$300k 20%
Founder salary + ops

18 months runway

$250k 17%
Protein validation

E. coli / Pichia expression, purification, BLI/SPR

$200k 13%
Chip prototyping

SU-8 masters, PDMS, photomasks, microscope time

$150k 10%
IP legal

Non-provisional conversion + FTO · US + PCT option

$100k 7%
Contingency (15%)

Unforeseen costs

$100k 7%
Total $1,500k 100%

Next Round

Series A · $5M · Q4 2027

Scale production · Hire sales · Enter pharma pilots

Alongside the seed

Sivoro is also pursuing non-dilutive federal funding to support the validation gates. Any award would extend runway rather than replace the round.

Key Risks & Mitigations

Mitigation

Linker-length and fusion-terminus series, evaluated by the same assay (SEC-MALS). HEX1 oligomerization is well-characterized in the native protein; the open question is whether the fusion preserves it.

Mitigation

Motif-presentation series and an alternative sterically caged binding module. This is the highest-risk element of the program and our structure prediction is inconclusive (ipTM 0.18).

Mitigation

Morphological characterization precedes chip loading. Contingency: alternative promoters or partial truncations that preserve optogenetic response without a growth penalty.

Mitigation

Chassis work is sequenced after valve validation and does not gate it. Measured orthogonality is characterized before chip integration rather than assumed from the model.

Ready to Learn More?

Download the pitch deck, or reach out directly to schedule a conversation.

Download Pitch Deck (PDF) Light version (PDF) [email protected]

New York, New York · Seed round Q1 2027 · Pre-money $6M